NASDAQ:TVTX

Travere Therapeutics Stock Insider Trading

etoro logo Buy TVTX
*Your capital is at risk
$45.20
+2.24 (+5.21%)
At Close: Jun 03, 2026

Travere Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -70.32. In total, the insiders bought 712.5K and sold 296.71K TVTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
-70.32
Buy 712.5K shares
Sell 296.71K shares
72% Buy Activity
Moderate Negative Correlation
Sell Signal High Confidence
Feb 03, 2026

Analysis Breakdown:

  • Strongly supported by a very low Insider Power Score of -70.32.
  • Partially supported by a negative historical correlation.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
May 19, 2026
Buy
Common Stock
A-Award
Williams Brinkley Ruth
Director
Director 4 000
Value: $169.0K
May 19, 2026
Buy
Stock option (right to buy)
A-Award
Squarer Ron
Director
Director 12 000
Value: $507.1K
May 19, 2026
Buy
Stock option (right to buy)
A-Award
Poole Sandra
Director
Director 12 000
Value: $507.1K
May 19, 2026
Buy
Stock option (right to buy)
A-Award
Bruhn Suzanne Louise
Director
Director 12 000
Value: $507.1K
May 19, 2026
Buy
Common Stock
A-Award
Bruhn Suzanne Louise
Director
Director 4 000
Value: $169.0K
May 19, 2026
Buy
Stock option (right to buy)
A-Award
Coughlin Timothy
Director
Director 12 000
Value: $507.1K
May 19, 2026
Buy
Common Stock
A-Award
Coughlin Timothy
Director
Director 4 000
Value: $169.0K
May 19, 2026
Buy
Stock option (right to buy)
A-Award
Lyons Gary A
Director
Director 12 000
Value: $507.1K
May 19, 2026
Buy
Common Stock
A-Award
Lyons Gary A
Director
Director 4 000
Value: $169.0K
May 19, 2026
Buy
Stock option (right to buy)
A-Award
Meckler Jeffrey A
Director
Director 12 000
Value: $507.1K
May 19, 2026
Buy
Stock option (right to buy)
A-Award
Baynes Roy D.
Director
Director 12 000
Value: $507.1K
May 19, 2026
Buy
Common Stock
A-Award
Baynes Roy D.
Director
Director 4 000
Value: $169.0K
May 19, 2026
Buy
Common Stock
A-Award
Poole Sandra
Director
Director 4 000
Value: $169.0K
May 19, 2026
Buy
Common Stock
A-Award
Squarer Ron
Director
Director 4 000
Value: $169.0K
May 19, 2026
Buy
Stock option (right to buy)
A-Award
Williams Brinkley Ruth
Director
Director 12 000
Value: $507.1K
May 19, 2026
Buy
Common Stock
A-Award
Meckler Jeffrey A
Director
Director 4 000
Value: $169.0K
May 19, 2026
Buy
Stock option (right to buy)
A-Award
Orwin John A
Director
Director 12 000
Value: $507.1K
May 19, 2026
Buy
Common Stock
A-Award
Orwin John A
Director
Director 4 000
Value: $169.0K
May 15, 2026
Sell
Common Stock
S-Sale
Coughlin Timothy
Director
Director 3 250
Value: $141.3K
May 06, 2026
Sell
Common Stock
S-Sale
Dube Eric M
Chief Executive Officer
CEO / President 22 500
Value: $988.9K
May 06, 2026
Sell
Common Stock
S-Sale
Rote William E.
Chief Research Officer
Officer 2 763
Value: $121.4K
May 06, 2026
Sell
Common Stock
S-Sale
Inrig Jula
Chief Medical Officer
Officer 311
Value: $13.7K
May 06, 2026
Sell
Common Stock
S-Sale
Reed Elizabeth E
Chief Legal Officer And GC
Officer 2 076
Value: $91.2K
May 06, 2026
Sell
Common Stock
S-Sale
Cline Christopher R.
Chief Financial Officer
C-Suite Officer 310
Value: $13.6K
May 05, 2026
Sell
Common Stock
S-Sale
Heerma Peter
Chief Commercial Officer
Officer 2 174
Value: $101.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT TRAVERE THERAPEUTICS, INC.
Travere Therapeutics
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzy...
GOLDEN STAR
Ticker Change Signal Date
RUN
$12.83
18.86% May 06
GLBE
$31.61
5.35% May 05
SAP
$172.39
10.69% May 05
W
WCLD
$27.34
27.18% Apr 29
ADBE
$243.57
7.61% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE